𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease

✍ Scribed by J.E. Nash; S.H. Fox; B. Henry; M.P. Hill; D. Peggs; S. McGuire; Y. Maneuf; C. Hille; J.M. Brotchie; A.R. Crossman

Book ID
115607309
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
73 KB
Volume
165
Category
Article
ISSN
0014-4886

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Topiramate reduces levodopa-induced dysk
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease
✍ Monty A. Silverdale; S.L. Nicholson; A.R. Crossman; J.M. Brotchie 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

## Abstract Overactive AMPA receptor‐mediated transmission may be involved in the pathogenesis of levodopa‐induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor‐mediated transmission. In this study, the potential antidyskinetic actio

The selective mu-opioid receptor antagon
The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease
✍ James B. Koprich; Susan H. Fox; Tom H. Johnston; Allan Goodman; Bertrand Le Bour 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB

## Abstract In Parkinson's disease (PD), dyskinesia develops following long‐term treatment with 3,4‐dihydroxyphenylalanine (L‐dopa). Given the prominent role of the opioid system in basal ganglia function, nonselective opioid receptor antagonists have been tested for antidyskinetic efficacy in the

Antiparkinsonian activity of (+)-PHNO in
Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset
✍ M. Nomoto; S. Stahl; P. Jenner; Dr. C. D. Marsden 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 542 KB

Administration of MPTP (1-4 mg/kg ip daily for 5-7 days) to common marmosets induced persistent parkinsonian motor deficits. The subcutaneous administration of ( + )-PHNO [( + )-4-propyl-9-hydroxynaphthoxazine; 1-4 ~g / k g ] caused a dose-dependent reversal of the akinesia and incoordination of mov